ASYS

Amtech Systems Inc

NASDAQ

Add Alert

4.83

-0.16 (-3.21%)

ASYS

Amtech Systems Inc

NASDAQ

Add Alert

4.83

-0.16 (-3.21%)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Porterhouse10

05/25/23 7:00 PM

Post #97

Looky looky Charts a Monster!

Porterhouse10

01/19/23 3:37 PM

Post #96

Come back to $8 $ASYS

Porterhouse10

12/01/22 9:56 AM

Post #95

Always sells off after earnings, come on down $$$$$

Porterhouse10

11/11/22 5:45 PM

Post #94

Missed bigger profits, but took nice green $ASYS $10.39 at time of post, sold @ $9.92

Porterhouse10

11/09/22 1:35 PM

Post #93

Sold $9.92, wait for re entry $ASYS

Porterhouse10

11/08/22 1:36 PM

Post #92

$9.92 at time of post, how them low -mid $8's lookin $ASYS BOOM

Porterhouse10

10/27/22 10:11 AM

Post #91

And BOOM buys $8.05, $8.44, now @ $9.38 at time of Post $ASYS

Porterhouse10

10/25/22 1:06 PM

Post #90

Fixing to add again $ASYS

Porterhouse10

10/06/22 9:47 AM

Post #89

Who said the load zone was $8.05? Boom $ASYS

Porterhouse10

09/30/22 9:37 AM

Post #88

And there is is #ASYS Reload zone

Porterhouse10

09/22/22 2:07 PM

Post #87

Come back to $8.05 for another boat load $ASYS

Porterhouse10

08/22/22 5:46 PM

Post #86

Boom boom AH $13.44

Porterhouse10

08/19/22 6:38 PM

Post #85

Yep and yep high of $12.50 intraday

Porterhouse10

08/18/22 5:03 PM

Post #84

Told ya! $11.17 close $ASYS

Porterhouse10

08/15/22 6:18 PM

Post #83

And Boom

Porterhouse10

08/12/22 3:51 PM

Post #82

Mmmm hmmmm

Porterhouse10

08/03/22 4:04 PM

Post #81

Alerted $7.02

Porterhouse10

07/29/22 5:04 PM

Post #80

Nice move today, low low volume, but I'll take it $ASYS

Porterhouse10

07/07/22 5:43 PM

Post #79

Quiet little gem added today, when the slam on Semi's stops and it will, watch this!

Porterhouse10

07/01/22 8:52 PM

Post #78

Added $58 mill in backlog

Porterhouse10

05/19/22 1:50 PM

Post #77

Love this little no namer $ASYS

Porterhouse10

05/13/22 3:15 PM

Post #76

Loaded the boat here yesterday @$7.02, no brainer growth YOY, QOQ, $53 MILL in backlog work, earned 24mill for the Quarter in earnings.

Porterhouse10

03/24/22 5:22 PM

Post #75

Like I told ya $ASYS

Porterhouse10

03/16/22 3:37 PM

Post #74

Spring Loaded Jmo

Porterhouse10

03/09/22 3:05 PM

Post #73

Headed for Primetime jmo

Porterhouse10

03/02/22 6:14 PM

Post #72

This thing is gonna blast off if they beat

Porterhouse10

01/19/22 12:47 PM

Post #71

Mmmm, might be time soon!

Porterhouse10

12/23/21 9:22 PM

Post #70

Still no one? Ok

Porterhouse10

09/28/21 11:26 AM

Post #69

Gonna be adding here SOOON!

Porterhouse10

09/14/21 12:24 PM

Post #68

Add back in $10's

Porterhouse10

09/10/21 9:57 AM

Post #67

Here we Go!

Porterhouse10

09/07/21 9:41 AM

Post #66

Blue sky breakout!

Porterhouse10

08/27/21 2:17 PM

Post #65

Come on Baby, back to $14, chart is strong Dong!

Porterhouse10

08/26/21 7:29 PM

Post #64

This Crunch is real, exciting, hoping for good Semiconductor news! But I'm in! Chart Monsta!

Porterhouse10

08/25/21 4:18 PM

Post #63

Crunch time, what's it gonna be!?

Porterhouse10

08/05/21 8:04 AM

Post #62

Nice Financials! The big BEAT!

Porterhouse10

08/02/21 1:01 PM

Post #61

Time to add

Porterhouse10

07/30/21 10:54 AM

Post #60

Here we go into earnings Aug 4th!

Porterhouse10

06/25/21 7:07 AM

Post #59

The march north here

Porterhouse10

05/26/21 10:43 AM

Post #58

Boom boom

Porterhouse10

05/24/21 10:56 AM

Post #57

Make that turn North!

Porterhouse10

05/15/21 10:48 PM

Post #56

Re: #1: @Penny Roger$ - Amtech Systems, Inc. (Amtech) is a global provider

I'm in

Porterhouse10

05/15/21 10:46 PM

Post #55

Re: #46: @mirza3 - IN WITH 30K TODAY 8.25 WENT ABOVE 10SMA

Bitchin' Camaro

Porterhouse10

05/15/21 9:48 AM

Post #54

Added

Porterhouse10

04/22/21 5:23 PM

Post #53

Adding

makinezmoney

06/07/20 5:24 AM

Post #52

$ASYS: Investor Presentation...............

www.amtechsystems.com/pdf/2019/amtech_presentation_111919.pdf

GO $ASYS

willlbone

01/30/20 2:12 PM

Post #51

Watch out for trap door.

whytestocks

12/27/19 4:45 PM

Post #50

News: $ASYS Amtech Provides Update on Timing of Sale of Solar Business

TEMPE, Ariz. , Dec. 27, 2019 /PRNewswire/ -- Amtech Systems, Inc. (NASDAQ: ASYS), a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips...

In case you are interested ASYS - Amtech Provides Update on Timing of Sale of Solar Business

whytestocks

06/28/19 1:40 PM

Post #49

News: $ASYS Amtech Announces the Sale of its SoLayTec Solar Business

TEMPE, Ariz. , June 28, 2019 /PRNewswire/ -- Amtech Systems, Inc. (NASDAQ: ASYS), a manufacturer of capital equipment, including thermal processing and wafer handling automation, and related consumables used in fabricating semiconductor devices, light-emitting diodes (LEDs), silicon carbi...

Find out more https://marketwirenews.com/news-releases/amtech-announces-the-sale-of-its-solaytec-solar-business-8430018.html

swanlinbar

07/02/18 3:34 PM

Post #48

ASYS took a shot & bought a few @5.99

Older

Amtech Systems Inc (ASYS)

Followers	5	Posters	11
Posts (Today)	0	Posts (Total)	97
Created	02/06/12	Type	Free
Moderators

Amtech Systems, Inc. (Amtech) is a global provider of thermal processing systems, including related automation, parts and services for the solar/photovoltaic, semiconductor, silicon wafer and microelectromechanical systems (MEMS) industries. It designs, assembles, sells and installs capital equipment and related consumables used in the manufacture of wafers, primarily for the solar and semi-conductor industries. It sells these products to manufacturers of solar cells, silicon wafers, and semi-conductors worldwide, particularly in Asia, United States and Europe. It also offers plasma-enhanced chemical vapor deposition (PECVD) and phosphorus silicate glass (PSG) equipment. It manufacture polishing templates, steel carriers and double-sided polishing and lapping machines to fabricators of light-emitting diodes (LED’s), optics, quartz, ceramics and metal parts, and for manufacturers of medical equipment components. On February 18, 2011, the Company acquired a 55% interest in Kingstone. http://www.google.com/finance?q=ASYS#

ASYS

Amtech Systems Inc

4.83

-0.16 (-3.21%)

Volume:	44,326
Day Range:	4.78 - 4.9877
Last Trade Time:	4:05:02 PM EDT

Delayed by 15 minutes

ASYS Detailed Quote

ASYS Latest News

Form 4 - Statement of changes in beneficial ownership of securities
03/21/2025 06:53:27 PM
Form S-8 - Securities to be offered to employees in employee benefit plans
03/19/2025 02:48:34 PM

More ASYS News

New Post

Play Episode

5min

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Proactive - Interviews for investors

EBR Systems nears FDA approval for CRT pacemaker

EBR Systems Inc Senior Vice President Andrew Shute talked with Proactive at the AIM maSmall and Midcap Conference about the company’s upcoming FDA decision for its leadless CRT pacemaker system. The device is designed to treat heart failure and represents the only leadless option in a market currently dominated by three players—with no direct competitor. Shute said, “We've developed the world's only leadless pacemaker to treat heart failure. And we're on track to receive FDA approval within the next two and a half weeks.”* The product already holds FDA Breakthrough Device designation, and has shown strong clinical results, including a 16.4% reduction in left ventricular end systolic volume—well above the target goal of 9.3%. Shute outlined the company's go-to-market plan, emphasizing that reimbursement is expected to begin from October 1st under the NTAP and TPT schemes, enabling an ASP of USD 45,000. The company only needs to sell around 2,200 units annually to reach USD 100 million in revenue. “We’ve got no direct competition,” he said. He also highlighted the successful completion of the FDA’s pre-approval inspection with no observations—an uncommon achievement in the medical device industry. The device, supported by data published in JAMA Cardiology, was also featured at the Heart Rhythm Society meeting in 2023. During the interim, the US commercial team will establish purchasing agreements, prepare technology committee engagements, and begin physician training for a limited market release. #EBRSystems #MedicalDevices #HeartFailureTreatment #LeadlessPacemaker #CardiacTech #FDAApproval #CRTDevice #InvestingInHealthcare #BreakthroughDevice #MedTechInnovation #JAMACardiology #HeartRhythmSociety

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Amtech Systems Inc (ASYS)

ASYS Detailed Quote

ASYS Latest News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Amtech Systems Inc (ASYS)

ASYS Latest News

Go Ad-Free